Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mochida Pharmaceutical Co., Ltd. ( (JP:4534) ) has issued an announcement.
Mochida Pharmaceutical Co., Ltd. reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a 2.2% increase in net sales to ¥105,159 million. The company achieved significant growth in operating profit, which rose by 40.1% to ¥8,126 million, and ordinary profit, which increased by 33.6% to ¥8,067 million. Despite a decrease in comprehensive income, the company maintained stable dividend payments and improved its financial position with a higher equity-to-asset ratio.
More about Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and sale of pharmaceutical products. The company is listed on the Tokyo Stock Exchange and is known for its contributions to healthcare through innovative drug development.
YTD Price Performance: -11.03%
Average Trading Volume: 26,864
Technical Sentiment Signal: Sell
Current Market Cap: Yen105.3B
See more data about 4534 stock on TipRanks’ Stock Analysis page.